Primary Myelofibrosis - 13 Studies Found
Terminated |
: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) : Primary Myelofibrosis : 2014-03-06 : Drug: Ruxolitinib Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. lo |
Completed |
: Thalidomide in Treating Patients With Myelofibrosis : Primary Myelofibrosis : 2001-05-06 :
|
Withdrawn |
: A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis : Primary Myelofibrosis : 2015-10-21 : Biological: Pacritinib QD (Once a day) |
Active, not recruiting |
: Decitabine in Treating Patients With Myelofibrosis :
|
Recruiting |
: P1101 in Treating Patients With Myelofibrosis :
|
Active, not recruiting |
: Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence : Primary Myelofibrosis : 2010-07-15 :
|
Recruiting |
: Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis :
|
Completed |
: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis : Primary Myelofibrosis (MF) : 2014-03-12 : Drug: Ruxolitinib |
Recruiting |
: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis :
|
Completed |
: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis :
: 2011-06-09 : Drug: IPI-926 Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive dise |